Spontaneous intracranial hemorrhage is a debilitating form of stroke, often leading to death or permanent cognitive impairment. Many of the causative genes and the underlying mechanisms implicated in developmental cerebral-vascular malformations are unknown. Recent in vitro and in vivo studies in mice have shown inhibition of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway to be effective in stabilizing cranial vessels. Using a combination of pharmacological and genetic approaches to specifically inhibit the HMGCR pathway in zebrafish (Danio rerio), we demonstrate a requirement for this metabolic pathway in developmental vascular stability. Here we report that inhibition of HMGCR function perturbs cerebral-vascular stability, resulting in progressive dilation of blood vessels, followed by vessel rupture, mimicking cerebral cavernous malformation (CCM)-like lesions in humans and murine models. The hemorrhages in the brain are rescued by prior exogenous supplementation with geranylgeranyl pyrophosphate (GGPP), a 20-carbon metabolite of the HMGCR pathway, required for the membrane localization and activation of Rho GTPases. Consistent with this observation, morpholino-induced depletion of the b-subunit of geranylgeranyltransferase I (GGTase I), an enzyme that facilitates the post-translational transfer of the GGPP moiety to the C-terminus of Rho family of GTPases, mimics the cerebral hemorrhaging induced by the pharmacological and genetic ablation of HMGCR. In embryos with cerebral hemorrhage, the endothelial-specific expression of cdc42, a Rho GTPase involved in the regulation of vascular permeability, was significantly reduced. Taken together, our data reveal a metabolic contribution to the stabilization of nascent cranial vessels, requiring protein geranylgeranylation acting downstream of the HMGCR pathway.
Introduction
HMGCR catalyzes the rate-limiting step in the conversion of HMGCoA to mevalonate, giving rise to mevalonate-derived molecules including cholesterol and isoprenoids (Goldstein and Brown, 1990) . A complex feedback mechanism involving both steroidal and non-steroidal mediated pathways is involved in the regulation and maintenance of HMGCR activity (Brown and Goldstein, 1997; Nakanishi et al., 1988 , Omkumar et al., 1994 DeBose-Boyd, 2008) . Statins, competitive inhibitors of HMGCR, are pharmaceuticals that bind part of the HMG-binding residues of the enzyme and inhibit its activity (Istvan and Deisenhofer, 2001 ). In addition to lowering cholesterol levels, statins also curtail the biosynthesis of other lipids, namely isoprenoids, which otherwise serve as essential lipid attachments for the Rho family of GTPases (Bishop and Hall, 2000) . Hence, an efficient way to elucidate HMGCR gene function during development is to use statins for which the biochemical mode of action is well characterized. Deficiencies in HMGCR activity during development are implicated in prenylation-dependent germ cell migration delay and misguidance in both Drosophila and zebrafish (Danio rerio) models (Santos and Lehmann, 2004; Thorpe et al., 2004) . A point mutation identified at position 1575 of hmgcrb, the maternally-expressed hmgcr paralog in zebrafish, results in defective heart-tube formation due to impaired post-translational prenylation of small GTPases (D'amico et al., 2007) . In contrast, targeted disruption of hmgcr in mice results in early embryonic lethality, which is indicative of the crucial function that HMGCRmediated metabolism and downstream signalling events play during mammalian development (Ohashi et al., 2003) . Presently, the developmental processes that require adequate HMGCR function remains poorly understood.
Pharmacological inhibition of the HMGCR pathway was shown to exert both angiostatic and angiogenic effects in vitro (Lu et al., 2004; Khaidakov et al., 2009; Weis et al., 2002; Kaneta et al., 2003; Li et al., 2002; Acquavella et al., 2009 ). An outstanding question is whether perturbations of the HMGCR pathway would disrupt the stabilization of nascent vessels and overall vascular morphogenesis in vivo, and, Contents lists available at SciVerse ScienceDirect journal homepage: www.elsevier.com/locate/developmentalbiology
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if so, what would be the pathophysiological consequences of interference with these processes during a period of rapid angiogenesis. Zebrafish have recently been utilized as a suitable model to dissect the etiology of cerebral cavernous malformation (CCM) (Kleaveland et al., 2009; Hogan et al., 2008; Yoruk et al., 2012) . Moreover, recent work in zebrafish demonstrates that proteins involved in the activation and transduction of Rho GTPase-mediated signalling pathways synergistically participate in the development of the vascular network in zebrafish. Deficiencies within this pathway impair the stabilization and maturation of nascent vessels by preventing the association of mural cells with endothelial cells, giving rise to multiple hemorrhages in the brain (Buchner et al., 2007; Liu et al., 2007) , along with more pronounced defects in vascular morphogenesis (Epting et al., 2010) . It is known that the mevalonate-derived metabolite, geranylgeranylpyrophosphate (GGPP) serves as an end-product for the lipidation and subcellular localization of Rho GTPases to the plasma membrane, which is critical for their activation and function (Bishop and Hall, 2000) . Hence, depleted GGPP levels reduce the GTP-binding capacity of Rho GTPases, rendering them cytosolic and inactive. Although the Rho GTPase pathway has been implicated in CCM pathology, there is discrepancy between the mechanisms in mouse and zebrafish. More specifically, studies in mice show that global inhibition of Rho GTPase prenylation via statin-mediated blockage of the HMGCR pathway restores endothelial barrier integrity, thus reversing the vascular permeability dysfunction in mice that are genetically predisposed for CCM (Whitehead et al., 2009) . Consistent with this observation, transcript levels of the Rho GTPases, RhoA, Rac and cdc42, were significantly elevated in lesions of a mouse model of CCM (Louvi et al., 2011) . Hence, in mice, statin-mediated inhibition of Rho GTPase signalling, through decreased GGPP biosynthesis, is reported to be an effective treatment to attenuate vascular permeability (Li and Whitehead, 2010) , whereas in zebrafish, mutation and morpholino induced loss of function of proteins that participate in the activation and transduction of Rho GTPase signalling promotes vascular permeability (Buchner et al., 2007; Liu et al., 2007) .
To further investigate this discrepancy, we used two structurally different statin molecules and two morpholino oligonucleotides with non-overlapping sequences to inhibit zebrafish HMGCR function, all of which resulted in grossly dilated vessels, followed by progressive loss of vascular stability in the brain at specific developmental stages during which nascent cranial vessels are more prone to rupture. Prior supplementation with exogenous mevalonate or GGPP, two of the metabolites downstream of the HMGCR pathway, rescued the cerebral hemorrhage phenotype. Furthermore, morpholino-mediated specific disruption of the GGTase I-mediated prenylation pathway also mimicked the cerebral hemorrhages attributed to the inhibition of the HMGCR pathway. Interestingly, in embryos with cerebral hemorrhage, the vascular-specific expression of cdc42, a Rho GTPase implicated in the mediation of endothelial barrier function (Kouklis et al., 2003; Broman et al., 2006; Ramchandran et al., 2008; Spindler et al., 2010) and highly enriched on the vacuole membranes (Eitzen et al., 2001; Isgandarova et al., 2007) , was noticeably reduced in the head and trunk vasculature, as early as 24 hpf. Our results highlight a requirement for HMGCR metabolism, through GGPP biosynthesis, to the establishment of cerebral-vascular stability during zebrafish development, likely mediated by CAAX proteins that require geranylgeranylation for their activation.
Materials and methods

Zebrafish husbandry and transgenic lines
Adult zebrafish were maintained under a constant temperature of 28 1C and a 14 h light: 10 h dark photoperiod in the University of Ottawa Aquatic Care Facility. Embryos were obtained through natural breeding of adult zebrafish and were kept at 28. 
Drug treatment and metabolite rescue experiments
For pharmacological inhibition of HMGCR, zebrafish embryos (1-2 hours post fertilization; hpf) were treated with Atorvastatin (ATV; Pfizer Inc., Connecticut USA) or Cerivastatin (CVT; Sequoia Research Products Ltd. Pangbourne, UK) in a single-exposure manner in embryo medium. ATV was dissolved in DMSO, whereas CVT was dissolved in sterile/distilled water. All solutions were aliquoted and kept at À 20 1C until used. Embryos for the dose-response experiments were placed in final concentrations of 0.3, 0.5 or 1 mg/L ATV; CVT was administered at 0.15 mg/L. For mevalonate rescue experiments, similar numbers of embryos were placed in embryo medium containing 0.5 mg/L ATV and 1, 1.6, 3.2 or 4.4 mmol/L mevalonic acid (Sigma-Aldrich) or DMSO as vehicle control. Each treatment group consisted of more than 70 embryos and all exposure experiments were repeated at least 8 times. GGPP rescue experiments were performed by administering 0.5 mg/L ATV and 0.5, 2 or 4 mg/L GGPP (Sigma-Aldrich) dissolved in DMSO/methanol or DMSO/methanol, as vehicle control.
Whole-mount o-Dianisidine (OD) staining and cryosectioning
Zebrafish embryos at various developmental stages were fixed in 4% PFA/1X Phosphate Buffered Saline Tween-20 (PBST) overnight and subsequently stained for hemoglobin using o-Dianisidine, a sensitive marker of hemoglobin. Briefly, unfixed embryos were dechorionated and stained with a solution of OD (0.6 mg/mL) (Sigma-Aldrich) containing 0.01 M sodium acetate (pH 4.5), 0.65% hydrogen peroxide, and 40% (v/v) ethanol in the dark for 15 min. Treated embryos were visualized using a Nikon NBZ 1500 dissecting microscope with a Nikon DXM 1200 C digital camera and stored in 50% glycerol at 4 1C. For cryosectioning, whole-mount embryos previously stained with OD were equilibrated to 30% sucrose/1X PBST overnight. The next day, the samples were mounted in tissue freezing medium (Triangle Biomedical Sciences). Transverse sections of $10 mm thickness were cut on a Leica CM1850 standard cryostat (Leica Microsystems) at À20 1C.
Confocal microscopy
For confocal microscopy, 48-52 hpf Tg(flk1:EGFP;gata1:dsRED) embryos previously treated with ATV or DMSO were embedded in 1% low melting agarose in embryo medium and tricaine mesylate (ethyl 3-aminobenzoate methanesulfonate; Sigma-Aldrich).
A rendered Z-stack, at $ 80 mm thickness each, was taken with a Zeiss LSM 510 AxioImager.M1 confocal microscope using an Achroplan 40 Â /0.8 W objective with an argon laser (488 nm) and a helium-neon laser (543 nm).
Morpholino design, resuspension and microinjection
A splice-modifying antisense morpholino oligonucleotide against hmgcrb pre-mRNA (hmgcrb MO), a translation blocking morpholino oligonucleotide targeting the AUG initiation site of hmgcrb mRNA (AUG MO), a splice-modifying morpholino against pggt1b pre-mRNA (pggt1b MO), and a standard control morpholino against a splice targeting the human b-globin pre-mRNA (control MO), were obtained from GeneTools (Philomath, OR, USA). The sequences for the morpholinos used are:
0 ) (pggt1b-splice MO); and (5 0 -CCTCTTACCTCAGTTACAATTTATA-3 0 ) (control MO). All morpholino oligonucleotides were diluted in Danieau buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO 4 , 0.6 mM Ca(NO 3 ) 2 , 5.0 mM HEPES, pH 7.6) to a final concentration of 0.2 mM. The embryos were positioned in individual wells placed on a plate containing 1.0% agarose. The morpholino solution was then injected at quantities ranging from 0.5 to 10 ng into 1 to 2 cell-stage embryos through the cell-yolk boundary.
Microangiography
Briefly, 50-56 hpf embryos were anesthetized in tricaine mesylate (Sigma-Aldrich) and injected intra-vascularly with red fluorescent microspheres of 0.4 mm diameter (Thermo Scientific) through the sinus venosus and/or common cardinal vein. Fluorescence micrographs were acquired during a series of observations under the Nikon NBZ 1500 dissecting microscope, which was equipped with a standard dsRED filter set using a Nikon DXM 1200 C digital camera.
DAF-2DA staining
DAF-2DA (4-amino-5-methylamino-2 0 -7 0 -difluoro-fluorescein diacetate; Calbiochem) staining was performed as previously described (Lou et al., 2011) , with reduced incubation time.
In brief, live embryos were incubated in 10 mM DAF-2DA (in embryo medium, pH 7.0) and incubated for 5 h in the dark at 28.5 1C, after which fluorescence micrographs were acquired under the Nikon NBZ 1500 dissecting microscope, which was equipped with a standard GFP filter set, using a Nikon DXM 1200 C digital camera.
RNA extraction, RT-PCR and sequencing
Total RNA was harvested from a pool of embryos using TRIzol reagent (Invitrogen). The RNA was DNase-treated using the Deoxyribonuclease kit (Invitrogen) to minimize genomic DNA contamination. cDNA was synthesized from equal concentrations of RNA using a 1st Strand cDNA Synthesis Kit and M-MLV RT (Invitrogen) and used as a template in RT-PCR. PCR products were run on 1.75% agarose gels. Band intensities were quantified using ImageJ software. The primers used for PCR analysis were:
(5 0 -CAAACATGGGCTGGTTCAAG-3 0 ) (Elf1a forward) and (5 0 -AG TGGTTACATTGGCAGGG-3 0 ) (Elf1a reverse). The efficiency of the hmgcrb splice MO was assessed using primers flanking exon 3:
(5 0 -CCGTGACAATGTGCCTAATG-3 0 ) (hmgcrb forward) and (5 0 -CAGATCAATCAGCAGCAGGA-3 0 ) (hmgcrb reverse). The efficiency of the pggt1b splice MO was assessed using primers flanking exon 2:
(5 0 -TCTTCTGCCGGTCCATCC-3 0 ) (pggt1b forward) and (5 0 -GC GGTAGTGAGCGGTGAT-3 0 ) (pggt1b reverse). The PCR products were first separated by electrophoresis then excised from the gel and purified using the Qiagen gel purification kit (Qiagen), according to the manufacturer's instructions. Sequencing was performed to verify hmgcrb MO-induced splicing using the CEQ-8000 Genetic Analysis System and the aforementioned set of primers.
Results
Pharmacological inhibition of the HMGCR pathway leads to cerebralvascular defects in developing zebrafish
Sequence alignment of the partial catalytic sites of the HMGCR proteins revealed that the statin-binding residues (Istvan and Deisenhofer, 2001 ) are conserved in both zebrafish HMGCR paralogs (data not shown), which suggests functional conservation. We first used the Tg(fli1:EGFP;Gata-1:dsRED) line for the simultaneous visualization of the vascular network and the circulating erythrocytes during development. Treatment of these embryos with 0.5 mg/L ATV in embryo medium, starting at 1-2 hpf, in a singleexposure manner, did not affect the vascular patterning or morphology during 15-25 somite stage (data not shown). However, by 28 hpf, ATV treatment resulted in grossly dilated and diffusely shaped primitive cerebral-vessels of the forebrain and midbrain ( Fig. 1(A-E) and Fig. S1 (A-D) in supplementary material), in addition to the abnormal confinement of stagnant dsRED-positive erythrocytes and an attenuated circulation in the cerebral region ( Fig. 1F and G). These observations are indicative of impaired vessel wall function as the primary cause for the extravasation of erythrocytes at subsequent stages of development. Moreover, in these embryos the initial patterning of blood vessels was normal and no vascular regression or abnormal vessel patterning was observed, despite the presence of severely distended and bloodfilled vessels becoming evident as early as 26 hpf (Fig. S2A-F in  supplementary material) . Furthermore, the trunk vasculature and the formation of the segmental arteries were unaffected in these embryos, reflecting the cerebral-vascular specific nature of these effects at the doses of statins used (data not shown).
By 33 hpf, cerebral hemorrhage was evident in 46% of embryos (137/298). The locality and severity of the phenotype were variable in the brain, reflecting the multifocal nature of the hemorrhages ( Fig. 2A-D) . At 48 hpf, the extent of hematoma was evaluated with o-Dianisidine (OD), a sensitive marker of hemoglobin, which revealed extensive hemorrhaging in the forebrain, midbrain and the ventricular zone, along with appreciable reductions in the abundance of circulating erythrocytes in the pericardium, the sinus venosus and the tail region ( Fig. 2E and F) . Cross sections of embryos stained with OD at 48 hpf revealed hematomas predominantly in the telencephalon and tectum ( Fig. 2G and H) . The incidence of hemorrhages increased in a dose-dependent manner for ATV treatments (Fig. 2I ). These embryos eventually resolved the hemorrhages and resumed normal development ( Fig. S3A-H in supplementary  material) .
To confirm the vascular specificity of these defects, we performed confocal microscopy at 48-52 hpf on Tg(fli1:EGFP);(gata-1:DsRed) embryos, which revealed progressive leakage of erythrocytes from the prosencephalic artery (PrA) in ATV-treated embryos, and, when compared with the fully functional PrA observed in DMSO-treated embryos, the PrA in ATV-treated embryos supported only sluggish circulation (Fig. 3A-D) . Taken together, this confirms that the blood-filled and vastly enlarged nascent cranial vessels observed at 26-28 hpf (Fig. 1A-G) , are prone to leakiness and rupture at subsequent stages of development.
Loss of vascular integrity in the brain was further substantiated using fluorescence microangiography, which revealed that unlike the fully lumenized brain vasculature in DMSO-treated embryos (judged by the retention of the fluorescent microspheres in these vessels), ATV-treated embryos appeared to have less lumenization and also exhibited a general tendency to extravasate the injected microspheres at the sites of hemorrhage (Fig. 3E and F) , hence further attesting to the loss of vascular stability in the brain. We next sought to assess the smooth muscle cell coverage in these embryos using DAF-2 DA (4-amino-5-methylamino-2 0 -7 0 -difluoro-fluorescein diacetate; CALBIOCHEM), a membrane-permeable compound that reacts with nitric oxide (NO) to form the fluorescent DAF-2T, which is a marker for functional smooth muscle cell coverage in zebrafish (Zeng et al., 2009; Lou et al., 2011) . However, no vascular smooth muscle cell coverage was detected in the brain or trunk during the early stages of normal zebrafish development (data not shown), which suggests that nascent vessels are more prone to statin-induced hemorrhage, partly, by virtue of inadequate coverage with smooth muscle support. This observation is consistent with molecular and genetic evidence suggesting that the expression of early vascular smooth muscle cell markers in zebrafish are not detectable before the larval stage (Santoro et al., 2009; Seiler et al., 2010) .
We also exposed embryos at 1-2 hpf to Cerivastatin (CVT), a structurally different statin molecule with a comparable affinity for HMGCR (Istvan and Deisenhofer, 2001) . Waterborne exposure to CVT (0.15 mg/L), in a single exposure manner, resulted in 58% of embryos having cerebral hemorrhage by 33 hpf (108/174), which is a phenocopy of the ATV-treatment. To further test the specific nature of the pharmacological treatments, a metabolite rescue experiment was conducted using mevalonate, the immediate product of the HMGCR-catalysed reaction and a precursor of both cholesterol and isoprenoids. Treatment of 1-cell stage embryos with ATV (0.5 mg/L) in the presence of mevalonate (3.2 mmol/L) were sufficient to rescue the hemorrhage phenotype, as none of these embryos exhibited apparent hemorrhages (0/121). In contrast, 53% of the embryos treated with ATV (0.5 mg/L) in the presence of DMSO showed cerebral hemorrhage by 48 hpf (59/112). Treatment with mevalonate alone did not induce any overt developmental defects. The ability of mevalonate to rescue the phenotype suggests that deficiencies in one or more of the metabolites downstream of mevalonate within the HMGCR pathway may be implicated in the emergence of the hemorrhage phenotype.
Morpholino-mediated depletion of hmgcrb expression leads to cerebral-vascular defects in developing zebrafish
Zebrafish possess two paralogous genes encoding an HMGCR protein. The hmgcrb transcripts are maternally-enriched and exhibit a ubiquitous expression pattern throughout early embryogenesis, whereas hmgcra mRNA is only detected at 5 dpf and is confined to the liver and the anterior intestine (Thorpe et al., 2004) . To substantiate the phenotypic specificity of the statin-induced cranial vascular defects, we induced a transient loss of hmgcrb gene function with a morpholino oligonucleotide (MO) designed to hybridize with the third exon-intron boundary of the hmgcrb pre-mRNA (Fig. 4A) . The injection of 2 ng of this hmgcrb MO resulted in approximately 45% (91/203) of the embryos displaying cerebral hemorrhage at 48 hpf along with reduced abundance of erythrocytes in the pericardium and the sinus venosus as detected by whole-mount OD staining ( Fig. 4B and C) . The morphants demonstrated no other overt developmental defects and eventually recovered from the initial hemorrhage, further indicating that the impaired HMGCR pathway only affects cerebral-vascular development during a critical period when nascent vessels in the brain are more prone to rupture. This suggests that hmgcrb expression is dispensable in more mature vessels. Injection of higher quantities of the hmgcrb MO ( 48 ng) resulted in developmental arrest, defective angiogenesis in the trunk, lack of circulation and occasional pericardial edema, and most of these embryos lacked the cranial hemorrhage phenotype (data not shown). The efficiency of the genetic ablation of hmgcrb expression was tested at 48 hpf by RT-PCR (Fig. 4D) and sequencing (data not shown) using primers spanning the third exonintron boundary. As with the statin-treatment, the exogenous supplementation of these embryos with mevalonate nearly completely rescued the splice MO-induced vascular defects at 48 hpf, with only 2.2% of the morpholino-injected embryos (2 ng) bathed in mevalonate (4.4 mmol/L) showing cerebral vascular defects (7/ 318) at 48 hpf. A second MO directed against the AUG translationstart site also mirrored the statin-induced hemorrhaging (data not shown). Overall, these observations further support an essential role for HMGCR-mediated lipid metabolism in cerebralvascular morphogenesis.
A deficiency in GGPP biosynthesis and impaired GGTase I-facilitated prenylation of Rho GTPases leads to cerebral-vascular defects in developing zebrafish
We next tested the hypothesis that statin-induced defects in vascular stability were attributable to perturbations in GGPP biosynthesis. To test this hypothesis, 1-cell stage embryos were treated with ATV (0.5 mg/L) in the presence of geranylgeranylpyrophosphate (GGPP, 4 mg/L) or the vehicle (DMSO:methanol; 50:50, v/v), starting at 1-2 hpf. The addition of GGPP effectively rescued the hemorrhage phenotype, and by 48 hpf approximately 7% of the embryos co-administered with ATV and GGPP showed evident cerebral hemorrhages (9/131), compared with 56% of control embryos receiving ATV and the vehicle (80/143). The near-complete rescue of the vascular phenotype with GGPP supplementation suggests a requirement for prenylation in the establishment of developmental cerebral-vascular stability. To further demonstrate that decreased GGPP bioavailability underlies these cerebral-vascular defects, we selectively targeted the prenylation pathway. Prenylation of small GTPases, such as Rac1, RhoA and cdc42, is catalyzed by the cytosolic isoprenyl transferase, geranylgeranyl pyrophosphate I (GGTase I) (Peterson et al., 2006; Roberts et al., 2008) . The enzyme, GGTase I, catalyzes the transfer and binding of the 20-carbon geranylgeranyl isoprenoid to the cysteine-residue of the CAAX motif at the C-terminus of target Rho GTPases (Fig. 5A) .This coupling constitutes a critical step for the translocation of the Rho GTPases to the plasma membrane and interaction with other lipophilic proteins. To specifically impair this pathway, we injected a spliceblocking morpholino targeting the second exon-intron boundary of the pggt1b pre-mRNA, which encodes the b-subunit of GGTase I (Fig. 5B) . Injection of 2.5 ng of the pggt1b MO in 1-cell stage embryos resulted in 23% of the embryos showing cerebral hemorrhage by 48 hpf (49/213) ( Fig. 5C and D) , thus phenocopying, both spatially and temporally, the cerebral-vascular defect associated with the inhibition of HMGCR. Injection of higher doses of pggt1b MO (6 ng) only slightly increased the frequency of hemorrhages (28%, 51/180), but most of these embryos were developmentally delayed (data not shown). The efficacy of the pggt1b MO was tested by RT-PCR on total RNA harvested from 48 hpf embryos that were previously injected with 2.5 ng MO, and showed a near complete depletion of wild-type pggt1b transcripts (Fig. 5E and F) . The transcript levels of eif1a were assessed as an internal control (Fig. 5F ) and did not show major changes. Based on sequence analysis, we predicted that MO-induced alternative splicing of pggt1b exon 2 would result in a frame-shift, thereby introducing a premature termination codon (TAA) in exon-3, thus targeting this mRNA for nonsense-mediated decay.
These results support that depletion of the HMGCR pathway impairs cerebral-vascular stability due to reduced GGPP biosynthesis and the consequential decrease in the prenylation status and membrane targeting of CAAX proteins, which serve as substrates for GGTase I.
The molecular nature of these statin-induced vascular defects were further characterized by the use of the Tg(fli1:EGFP-cdc42wt) y48 line in which the expression of EGFP-cdc42 fusion protein shows a perivacuolar co-localization restricted to the endothelial cells (Kamei et al., 2006) . The protein cdc42, a RhoA GTPase, is implicated in the regulation of vacuole formation, lumenization and mediation of endothelial barrier function (Kouklis et al., 2003; Broman et al., 2006; Ramchandran et al., 2008; Spindler et al., 2010) and it requires geranylgeranylation, downstream of HMGCR pathway, for its activation (Peterson et al., 2006; Roberts et al., 2008) . Treatment of Tg(fli1:EGFFP-cdc42wt) y48 embryos with ATV at the 1-cell stage led to a noticeable reduction in intra-endothelial expression of EGFPcdc42 in the brain and the trunk as early as 24 hpf (data not shown).
The decline in vascular-specific EGFP-cdc42 expression was also clearly evident in the head and trunk vasculature of these embryos at 48 hpf ( Fig. 6A and B) , the stage when cerebral hemorrhage was most preponderant in statin-treated embryos. The attenuated EGFPcdc42 expression was further validated by measuring EGFP signal intensity using ImageJ software ( Fig. 6E and F) . We further established that the reduction in fluorescence intensity was not attributable to global developmental defects, vascular regression or defective angiogenesis resulting from a down-regulation of the fli promoter in Tg(fli1:EGFP-cdc42wt)
y48
, since the expression of fli1:EGFP was unaffected in response to statin treatment and the brain and trunk vessel morphology and segmental artery formation was unaltered (Fig. 6C and D) . Similarly, quantification of the EGFP signal intensity in these fish confirmed unaltered expression of fli1:EGFP protein in the head or trunk vessels ( Fig. 6G and H) . Together, these data reflect a specific reduction in cdc42 levels as a consequence of statin treatment. To investigate the localization of cdc42 in response to statin exposure, we performed confocal microscopy on 48-52 hpf Tg(fli1:EGFP-cdc42wt) y48 embryos. We focused our attention on ISVs due to the ease of imaging. Whereas the EGFP-cdc42 expression in DMSO-treated embryos exhibited perivacular localization, outlining the boundaries of the intercellular lumen in the ISVs, ATV-treated embryos had reduced EGFP-cdc42 expression in the ISVs and any expression was concentrated primarily at the base of the ISVs (Fig. 6I and J) . Taken together, our evidence suggests that the endothelial-specific expression of cdc42 is markedly reduced concomitant with the onset and expansion of hematoma in the brain.
Discussion
Through a combination of pharmacological blockers, metabolite rescue and genetic approaches, this study demonstrates that a transient disruption in the HMGCR pathway induces intracranial hemorrhaging in zebrafish at a predictable developmental stage. This cerebral vascular-specific phenotype was not associated with any other developmental abnormalities. Of particular clinical significance is that these embryos manifest certain pathophysiological features that closely resemble CCM pathologies in humans and mice, such as abnormally dilated and blood-filled cranial microvessels prior to the onset of extravasation, intracranial hemorrhaging and expansion of hematoma, along with evidence of thrombosis in the vicinity of the lesions. It is likely that inhibition of the HMGCR pathway perturbs signalling processes that mitigate the assemblage of angioblasts into nascent vascular tubes, thus making them more prone to rupture and leakage. Interestingly, the extravasation of blood components is only detected in the head, implying that the vessels in this region are more fragile at this developmental period, hence more easily ruptured. Since the onset of hemorrhage and the expansion of hematoma correspond to a period of rapid angiogenesis during which numerous newly formed blood vessels invade the brain (Isogai et al., 2001) , it is plausible that these nascent vessels that carry blood for the first time would lack adequate coverage with support cells, making them weak and prone to rupture. Consistent with this, DAF-2DA staining showed no positive signal for smooth muscle cells in the brain or trunk vasculature during early development consistent with previous studies (Santoro et al., 2009) , which suggests that inadequate endothelial contact with support cells can predispose these early vessels to statin-induced hemorrhage. We have shown, by fluorescence microangiography, that defects in the establishment of endothelial cell-to-cell associations contribute to the loss of vascular stability in these embryos ( Fig. 3E and F) . Consistent with this assertion, zebrafish deficient in VE-cadherin, an endothelial-specific adhesion protein located in cell-to-cell junctions and important for vessel stabilization, exhibit cerebral-vascular fragility and hemorrhaging at 48 hpf in zebrafish (Montero-Balaguer et al., 2009).
At higher doses (5-10 mg/L), we observed that statin treatment significantly inhibited angiogenic processes in the trunk, as evidenced by the incomplete or defective anterior to posterior sprouting of intersegmental vessels (ISV) emanating from the dorsal aorta (DA), thereby severely restricting circulation in the fish, and often resulting in pericardial edema (data not shown), with almost no cerebral hemorrhages observed. This leads us to speculate that at higher doses, statin-treatment affects endothelial survival and migration, whereas at lower doses, vascular stability in the brain is compromised, to which the hemorrhage phenotype attests. This is also confirmed through our reverse genetics approach, with high doses of hmgcrb MO inducing defective angiogenesis in the trunk.
It is intriguing that the temporal and spatial distribution of the vascular defects reported here are similar to those associated with the bbh and rhd mutations which were previously characterized in zebrafish (Buchner et al., 2007; Liu et al., 2007) . These fish were reported to have hypomorphic mutations in the pak2a and bpixA genes that encode for proteins involved in regulating the activity and mediating the function of the Rho GTPases, Rac and cdc42 (Buchner et al., 2007; Liu et al., 2007) . The disruption of vascular permeability in these embryos is consistent with the roles of Rac and Cdc42 in the maintenance and stabilization of endothelial barrier function (Spindler et al., 2010) . The similar nature of the hemorrhages described in zebrafish deficient in pak2a and bpixA and those we report here suggests a molecular interaction between the HMGCR pathway and Rho GTPase signalling in the regulation of developmental vascular stability. This is further supported by the fact that both Rac and cdc42 are natural substrates for the b-subunit of GGTase I, which facilitates their post-translational modification by the addition of a mevalonate-derived geranylgeranyl lipid, a critical step required for the activation of these Rho GTPases (Peterson et al., 2006; Roberts et al., 2008) . Interestingly, using the Tg(fli1:EGFPcdc42wt) y48 line in which cdc42 protein is over-expressed in an endothelial-specific manner, we observed a decrease in the expression of EGFP-cdc42 in the cerebral and trunk vessels upon treatment with statins. This decrease was evident as early as 24 hpf and persisted to the onset of hemorrhage. We showed that the reduction in fluorescence intensity was not attributable to global developmental defects or down-regulation of fli1 promoter activity, since examination of Tg(fli1:eGFP) embryos showed no apparent alterations in fluorescence intensity nor signs of defects in cranial or segmental angiogenesis. Collectively, this observation is suggestive of statininduced degradation of cdc42 expression in the vasculature, and it further this highlights in vivo how alterations of HMGCR activity can exert effects on the cellular dynamics of cdc42 expression. On the whole, the rescue of statin-induced hemorrhages by the addition of GGPP, along with the hemorrhage phenotype elicited by the disruption of GGTase I-mediated prenylation in zebrafish strongly highlight a requirement for HMGCR activity for the stabilization of nascent vessels during early angiogenesis. These data contrast, however with previous findings in mice. More specifically, in mice, the defective endothelial stability underlying CCM pathogenesis, thought to be mediated by RhoA hyperactivation, is greatly attenuated upon pharmacological ablation of the HMGCR pathway, possibly due to non-cholesterol dependent processes (Whitehead et al., 2009 ). This raises the possibility that modulation of HMGCR activity could be a therapeutic strategy to ameliorate CCM pathobiology (Li and Whitehead, 2010) . More recently using a separate murine model of CCM, a more specific pharmacological inhibition of RhoA activity, through direct targeting of the Rho kinase signalling pathway, was shown to be similarly effective in significantly reducing CCM genesis (McDonald et al., 2012 ). The hemorrhage phenotype described here does not induce lethality, as these embryos eventually resolve the brief disruption in vascular stability and resume normal development. This is in contrast with the embryonic lethality observed in mouse models of intracranial hemorrhage. Furthermore, the robust and spontaneous nature of the vascular phenotype described here, coupled with the early onset of hemorrhage, the rapid expansion of hematoma and the optical transparency and accessibility of all of these processes, aided by the presence of tissue-specific transgenic lines and the possibility for high resolution imaging, make this model applicable for elucidating the pathophysiology of CCM-like lesions at various stages of progression.
